Zacharon Pharmaceuticals

Zacharon Pharmaceuticals is a biotech company specializing in the development of therapeutics that target glycans, a class of carbohydrates critical to various biological processes. Founded in 2004, the company combines its expertise in glycobiology with a drug discovery platform to create small molecules that influence glycan and glycolipid metabolism. Initial funding came from NIH grants and individual investors, while recent Series A financing was secured from Avalon Ventures, a venture capital firm known for supporting early-stage life sciences companies. With this financial support and a focus on addressing significant unmet medical needs, Zacharon Pharmaceuticals aims to pioneer a new class of human therapeutics.